BMO Capital Starts Alder Biopharm (ALDR) at Outperform

November 10, 2016 4:18 PM EST Send to a Friend
BMO Capital initiates coverage on Alder Biopharm (NASDAQ: ALDR) with a Outperform rating and a price target of $42.00.Analyst Matthew ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login